Giessen, Germany – 17 March 2026 – Green Elephant Biotech has announced the market introduction of Archimedes® One, pioneering a new category known as the Dynamic Adherent Bioreactor. This innovative platform is set to enhance cell therapy manufacturing, and the company is introducing it ahead of its planned commercial launch later this year.
The Archimedes® One is designed to address a critical challenge in the field of cell therapy: the necessity of maintaining biological integrity while simultaneously achieving industrial scalability. This advancement is expected to significantly improve the efficiency and effectiveness of cell therapy production.
As the biopharmaceutical industry continues to evolve, the demand for more sophisticated manufacturing processes has become increasingly apparent. Green Elephant Biotech’s new platform aims to meet this demand by integrating cutting-edge technology with the principles of responsible research and innovation.
The introduction of Archimedes® One aligns with the industry’s shift towards more sustainable and ethical approaches in biotechnology. By optimising the manufacturing process, Green Elephant Biotech is not only contributing to the advancement of cell therapies but also promoting environmentally sustainable practices within the sector.
Investors and stakeholders in the biotechnology realm are encouraged to explore potential funding opportunities related to this innovation. Such advancements in technology can pave the way for future research and development initiatives.
For more information about funding opportunities in the biotechnology sector, please refer to the relevant channels that support research initiatives.
In summary, the launch of Archimedes® One by Green Elephant Biotech represents a significant milestone in the field of cell therapy manufacturing. The anticipation surrounding its commercial launch later this year highlights the ongoing commitment to technological advancement and ethical considerations in the biopharmaceutical industry.